摘要
他达拉非是一种新型的5型磷酸二酯酶(PDE5)抑制剂,口服用于治疗勃起功能障碍。本综述主要就他达拉非上市后有关治疗勃起障碍方面的临床研究结果作一全面分析。所有数据表明,他达拉非作为一种长效的PDE5抑制剂拥有令患者满意的治疗效果和良好的耐受性,同时还有不少潜在的药理效果,这些都有利于我们更好的发挥其临床价值。
A new type of phosphodiesterase 5 inhibitor, Tadalafil, has been used clinically to treat erectile dysfunction (ED). In this review, we analyzed the recent findings from the clinical trials on tadelafil in ED treatment. All data showed that oral tadalafil was an effective and well-tolerated therapeutic for ED, with many potential pharmacological actions. All this may help to give full play to the clinical value of tadalafil.
出处
《中华男科学杂志》
CAS
CSCD
北大核心
2009年第4期379-383,共5页
National Journal of Andrology